Predicting effectiveness of flu vaccination campaigns

February 9, 2010

A new study, published by Elsevier this month in Vaccine, describes a new method that assesses the impact and cost-effectiveness of a range of vaccination options. The model was applied to the 2009 Influenza H1N1 outbreak and predicted accurately in real-time when the epidemic would peak and who should be prioritized for vaccination.

Last year, an outbreak of a novel strain of linked to swine influenza was detected in Mexico. The infection has shown sustained human-to-human transmission across the world, leading the to declare an . Vaccines specific for have been successfully developed and the UK Joint Committee on Vaccination and Immunization recommended that high-risk individuals be prioritized for vaccination.

Decisions about extending vaccination to low-risk individuals are heavily debated and depend partly on the epidemiological impact and cost-effectiveness of such options. Marc Baguelin, Albert Jan Van Hoek and colleagues from the Health Protection Agency and the London School of Hygiene and Tropical Medicine in the UK describe how they fit a to the estimated number of cases in real-time to predict the effectiveness of alternative influenza vaccination strategies. Specifically, they show that, vaccination of high risk groups was probably very cost effective. However, the cost-effectiveness of vaccinating children depended on the progress of the epidemic and may be cost-effective in countries where a flu pandemic is not so far advanced.

"Given the present debates in different European countries about the legitimacy of the different choices of vaccination our paper is very topical", said Baguelin, "further it reinforces and expands a recent article in The Lancet as it also suggests that many more people than first thought were infected in the summer wave of the swine flu pandemic".

More information:
-- Marc Baguelin, Albert Jan Van Hoek, Mark Jit, Stefan Flasche, Peter J. White, and W. John Edmunds, Vaccination against pandemic influenza A/H1N1v in England: A real-time economic evaluation, 2010 Vaccine, Article In Press. doi:10.1016/s0140-67360.1016/j.vaccine.2010.01.002
-- Lancet paper: doi:10.1016/s0140-6736(09)62126-7

Related Stories

Recommended for you

Artificial beta cells

December 8, 2016

Researchers led by ETH Professor Martin Fussenegger at the Department of Biosystems Science and Engineering (D-BSSE) in Basel have produced artificial beta cells using a straightforward engineering approach.

Key regulator of bone development identified

December 8, 2016

Loss of a key protein leads to defects in skeletal development including reduced bone density and a shortening of the fingers and toes—a condition known as brachydactyly. The discovery was made by researchers at Penn State ...

Researchers question lifelong immunity to toxoplasmosis

December 8, 2016

Medical students are taught that once infected with Toxoplasma gondii—the "cat parasite"—then you're protected from reinfection for the rest of your life. This dogma should be questioned, argue researchers in an Opinion ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.